Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Uroplasty to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.
This table compares Uroplasty and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Uroplasty and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Uroplasty Competitors||$1.67 billion||$207.58 million||86.99|
Uroplasty’s peers have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Uroplasty has a beta of -1.26, indicating that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s peers have a beta of 0.47, indicating that their average share price is 53% less volatile than the S&P 500.
Insider and Institutional Ownership
54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Uroplasty and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Devices & Implants” companies have a potential upside of 37.60%. Given Uroplasty’s peers higher probable upside, analysts clearly believe Uroplasty has less favorable growth aspects than its peers.
Uroplasty peers beat Uroplasty on 6 of the 8 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
What are top analysts saying about Uroplasty Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Uroplasty Inc. and related companies.